Search

Displaying results 2191 - 2200 of 9667 in total
  1. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    It is commonly marketed under the brand name Fludara.

    Products: Fludarabine Kabi 50mg Lyophilized Powder for Solution for Injection or Infusion
  2. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    It is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.

    Products: Feiba 25 E./ml Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Feiba 50 E./ml Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
  3. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982) … Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.

  4. Drug

    Carboprost tromethamine

    go.drugbank.com/drugs/DB00429
    ApprovedInvestigational

    A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.

  5. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

  6. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: E-Z Cups, PMS-phosphates SolutionProducts: BT ORAL SOLUSYON 45 ML, BT ORAL SOLUSYON 90 ML
  7. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    al., PNAS 100:12590, 2003). … prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et

  8. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the … [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.

  9. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].

    Products: ERLEADA FILM-COATED TABLET 60MG, Erleada 60mg Film-Coated Tablets
  10. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively